NHP10 Antibody

What is rhesusization of antibodies and why is it necessary for NHP studies?

Rhesusization is an antibody reengineering process that converts human monoclonal antibodies to equivalent non-human primate (NHP) IgG subclasses. This process is essential when conducting passive transfer studies in NHPs because it minimizes anti-drug antibody (ADA) responses that can rapidly clear species-mismatched antibodies from circulation.

The process involves changing both the Fc and Fab sequences while maintaining the epitope specificity of the parent antibody. Simply grafting complementarity determining regions (CDRs) into an NHP IgG subclass can impact functionality, making rhesusization a challenging but necessary process for accurate NHP studies .

What are the main challenges in translating human antibody studies to NHP models?

Several key challenges exist when translating human antibody studies to NHP models:

• Interspecies differences: Host genetic differences between humans and NHPs can affect the type, magnitude, functionality, and duration of immune responses .

• Anti-drug antibody responses: Unmodified human antibodies administered to NHPs may trigger rapid ADA responses, particularly in longer trials .

• Fc-effector mismatch: Human antibodies may not interact optimally with NHP Fc receptors, potentially diminishing effector functions .

• Structural preservation concerns: Maintaining the structural integrity and epitope binding properties of antibodies during rhesusization is technically challenging .

• Strain differences: Discrepancies between circulating strains in human populations versus those in NHP challenge stocks can affect antibody effectiveness .

How can researchers verify preservation of epitope specificity after rhesusization?

Verification of epitope specificity preservation after rhesusization requires multiple complementary approaches:

• Structural analysis: Cryo-electron microscopy (cryo-EM) and X-ray crystallography should be used to confirm that rhesusized variants bind their respective antigens with identical specificity, preserving epitope footprints and maintaining critical antigen-Fab atomic contacts .

• Binding kinetics assessment: Surface plasmon resonance (SPR) should be employed to measure binding affinities and kinetics, ensuring comparable on/off rates between parent and rhesusized antibodies .

• Competitive binding assays: Researchers should conduct experiments to confirm that rhesusized antibodies compete with parent antibodies for the same epitope .

The structural data should demonstrate that the constant regions fold correctly as in control rhesus macaque IgG1s, while the variable regions maintain proper orientation and contact with the target antigen .

What methodologies are recommended for evaluating Fc effector functions of rhesusized antibodies?

A comprehensive assessment of Fc effector functions requires multiple functional assays:

• Antibody Dependent Cell-mediated Cytotoxicity (ADCC): Tests the ability of antibodies to direct immune cells to kill antibody-coated target cells .

• Antibody Dependent Cellular Phagocytosis by monocytes (ADCP): Evaluates the capacity of antibodies to enhance phagocytosis of target cells by monocytes .

• Antibody Dependent Cellular Phagocytosis by neutrophils (ADNP): Measures neutrophil-mediated phagocytosis of antibody-coated targets .

• Fc receptor binding assays: Assessments of binding to specific Fc receptors (FcγRIIa, etc.) should be conducted to ensure proper engagement .

These assays should compare the rhesusized antibodies to native macaque antibodies of similar specificity to ensure equivalent potency .

How should researchers design passive transfer studies to evaluate protective efficacy in NHP models?

When designing passive transfer studies in NHPs, researchers should implement the following methodological approaches:

• Antibody preparation: Use properly rhesusized antibodies to avoid species mismatch and ADA responses .

• Dosing considerations: Test multiple dosage levels to establish dose-response relationships .

• Timing optimization: Administer antibodies in both prophylactic (pre-exposure) and therapeutic (post-exposure) settings to evaluate different protection scenarios .

• Sample collection schedule: Collect samples at strategic timepoints to monitor antibody pharmacokinetics, target engagement, and immune responses .

• Challenge strategy: Use relevant challenge strains that reflect the diversity seen in human populations .

• Combination approaches: Consider testing antibody combinations rather than monotherapies to prevent emergence of escape variants, as demonstrated in REGEN-COV studies .

What crystallographic parameters are important when analyzing rhesusized antibody structures?

When performing crystallographic analysis of rhesusized antibodies, researchers should collect and report the following key parameters:

These crystallographic parameters are essential for assessing structural integrity and proper folding of rhesusized antibodies compared to their parent human antibodies .

How can researchers address the emergence of viral escape variants in antibody studies?

Researchers studying viral escape should implement these methodological approaches:

• Antibody combinations: Use non-competing antibody combinations targeting different epitopes to prevent selection of drug-resistant variants. For example, the REGEN-COV combination fully protected against development of resistance compared to individual antibodies, which rapidly selected for escape variants .

• Sequential passage experiments: Conduct multiple viral passages in the presence of antibodies to monitor for emergence of resistance .

• Genetic monitoring: Perform sequencing before and after treatment to identify mutations associated with resistance .

• Structural mapping: Map resistance mutations on antibody-antigen complex structures to understand mechanisms of escape .

• Triple-antibody approaches: Consider three-antibody combinations targeting non-overlapping epitopes, which have shown enhanced protection against viral escape without loss of potency through multiple passages .

What expression systems are recommended for producing recombinant antibodies for NHP studies?

The choice of expression system significantly impacts antibody functionality:

• Mammalian expression systems: Preferred for producing fully functional antibodies with proper glycosylation patterns. HEK293F Freestyle cells supplemented with Ultra Low IgG Fetal Bovine Serum are commonly used .

• E. coli expression systems: While convenient, these may yield antibodies with improper folding or post-translational modifications that fail to recognize native antigens, as demonstrated in bovine IL-2 antibody generation attempts .

• Cell culture conditions: Grow cells in appropriate medium (e.g., Freestyle 293 medium) supplemented with 2.5% Ultra Low IgG FBS in 8% CO2 for optimal expression .

• Purification methods: Utilize affinity chromatography followed by pH elution and buffer exchange to maintain antibody integrity .

Researchers should evaluate antibodies produced in E. coli versus mammalian systems, as E. coli-expressed antibodies may fail to detect antigen-induced responses despite binding to recombinant antigens in vitro .

How can researchers minimize anti-drug antibody responses in long-term NHP studies?

Minimizing anti-drug antibody (ADA) responses requires strategic approaches:

• Proper rhesusization: Complete rhesusization of both Fab and Fc regions to match the NHP IgG subclass is essential .

• Careful sequence design: Analyze and remove potential immunogenic sequences during antibody engineering .

• Quality control testing: Thoroughly evaluate antibody purity, aggregation, and endotoxin levels before administration .

• Administration protocols: Consider continuous infusion rather than bolus dosing to maintain steady antibody levels .

• Monitoring strategies: Implement regular monitoring for ADA responses throughout the study .

The risk of ADA responses increases with longer study durations, making proper antibody engineering particularly important for extended trials that may last weeks to months .

What are the key considerations when using rhesusized antibodies to understand correlates of protection in vaccine trials?

When investigating correlates of protection with rhesusized antibodies, researchers should consider:

• Epitope selection: Select antibodies targeting epitopes implicated in protection, such as those against HIV-1 envelope (Env) epitopes with potent Fc-effector function .

• Functionality preservation: Ensure preservation of both binding specificity and Fc-effector functions in rhesusized variants .

• Comparative analysis: Compare results from passive transfer studies with vaccine-induced responses to validate protection mechanisms .

• Infection models: Use challenge models that reflect the diversity and characteristics of human infections .

• Immune correlate assessments: Measure multiple potential correlates (antibody levels, ADCC, ADCP, ADNP, FcγR engagement) to identify the most relevant protection mechanisms .

This approach has been particularly valuable in HIV-1 vaccine research where Fc-effector functions like ADCP and FcγRIIa engagement correlated with reduced infection risk in human trials, suggesting these functions should be targeted in future vaccine designs .